Furthermore, MYD88 variants predominated in the IGHV M-CLL/SLL patients, indicating a potentially favourable prognosis in MYD88-mutated CLL/SLL patients, but previous studies showed that the prognostic impact of MYD88 variants in CLL/SLL was still discordant—multiple studies in CLL/SLL have shown MYD88 variants to have a favourable prognosis or no association with the course of disease, whereas others have shown MYD88 variants to be associated with a poor prognosis [23,24,25]. This evidence concerns the gene MYD88 and B-cell chronic lymphocytic leukemia.